Overview

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Status:
Not yet recruiting

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate the efficacy and safety of Toripalimab Injection in combination with chemotherapy compared to placebo in combination with chemotherapy in subjects with PD-L1-positive unresectable locally advanced or metastatic urothelial carcinoma who have received no previous systemic therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Junshi Bioscience Co., Ltd.

Treatments:

Carboplatin
Gemcitabine